Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
NCT ID: NCT07058675
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
156 participants
INTERVENTIONAL
2024-11-25
2025-06-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome
NCT01791647
Effects of Myo-inositol in Women With Polycystic Ovary Syndrome
NCT04892186
Insulin Sensitizers Role in Control of PCOS Vicious Cycle.
NCT06170463
Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome
NCT03566225
Chiglitazar/Metformin in Non-obese Women With PCOS
NCT06125587
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myoinositol Group
Patients presenting manifestations suggestive of having PCOS were evaluated for enrollment in the study, and took the tablets containing myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratio
Myoinositol
myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily
Metformin Group
Patients presenting manifestations suggestive of having PCOS were evaluated for enrollment in the study, and took metformin (MET) hydrochloride 500 mg
Metformin Hydrochloride 500 MG
metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin Hydrochloride 500 MG
metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.
Myoinositol
myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who were on medical therapy of PCOS, antidiabetic or/and antihypertensive therapy;
* Patients who underwent laparoscopic drilling;
* Patients with dyslipidemia, hereditary lipoprotein disorders:
* Patients with chronic liver or kidney diseases.
23 Years
47 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Basma Sakr
Assistant Professor of Obstetrics & Gynecology, Faculty of Medicine, Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha university
Banhā, El Qalyoubia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC 1-11-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.